COVID-19
COVID-19 treatments: under evaluation
The European Medicines Agency (EMA) is evaluating potential COVID-19 treatments to enable promising medicines to reach patients in the European Union (EU) as soon as possible.
EMA’s CHMP is evaluating marketing authorisation applications (which may be for conditional marketing authorisation) for the following COVID-19 treatments:
| Treatment | Applicant | Start of marketing authorisation evaluation | More information |
|---|---|---|---|
| Lagevrio (molnupiravir)* | Merck Sharp & Dohme and Ridgeback Biotherapeutics | 23/11/2021 |
*This medicine can already be used in the EU to treat COVID-19, after EMA's CHMP completed a review under Article 5(3) of Regulation (EC) No 726/2004. For more information, see:
Treatment developers have withdrawn the following COVID-19 treatments from the marketing authorisation evaluation process:
| Treatment | Treatment developer | Key milestones | More information |
|---|---|---|---|
| Olumiant (baricitinib) | Eli Lilly Nederland B.V. | Marketing authorisation evaluation started: 23/11/2021 Withdrawn from marketing authorisation evaluation: 07/12/2022 | Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2022 |
Treatment developers have withdrawn the following COVID-19 treatments from the rolling review process:
| Treatment | Treatment developer | Key milestones | More information |
|---|---|---|---|
| Bamlanivimab and etesevimab | Eli Lilly | Rolling review started: 11/03/2021 Withdrawn from rolling review: 29/10/2021 | Latest news Paediatric investigation plan for bamlanivimab Paediatric investigation plan for etesevimab |